Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules

BACKGROUND: Enzastaurin, an oral serine–threonine kinase inhibitor, was initially developed as an ATP-competitive selective inhibitor against protein kinase Cβ. However, the mechanism by which enzastaurin contributes to tumourigenesis remains unclear. METHODS: We analysed the anti-tumour effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimokawa, T, Seike, M, Soeno, C, Uesaka, H, Miyanaga, A, Mizutani, H, Kitamura, K, Minegishi, Y, Noro, R, Okano, T, Yoshimura, A, Gemma, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305973/
https://www.ncbi.nlm.nih.gov/pubmed/22333600
http://dx.doi.org/10.1038/bjc.2012.7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305973/
https://www.ncbi.nlm.nih.gov/pubmed/22333600
http://dx.doi.org/10.1038/bjc.2012.7

Ejemplares similares